Cover Image
市場調查報告書

皮膚疾病的治療技術·全球市場

Skin Disease Treatment Technologies and Global Markets

出版商 BCC Research 商品編碼 271121
出版日期 內容資訊 英文 128 Pages
訂單完成後即時交付
價格
Back to Top
皮膚疾病的治療技術·全球市場 Skin Disease Treatment Technologies and Global Markets
出版日期: 2016年01月01日 內容資訊: 英文 128 Pages
簡介

本報告提供全球皮膚疾病治療市場相關調查分析,提供包含實際成果·估計資料及年複合成長率預測的市場趨勢分析,皮膚疾病的4大分類(皮膚炎·癌症·免疫疾病疾病·感染疾病)分析,皮膚結構·功能,特定的皮膚疾病得病率的上升與新的診斷·治療選擇相關討論,各類別產品的市場分析,並彙整主要企業簡介等,為您概述為以下內容。

第1章 簡介

第2章 摘要

第3章 概要

  • 皮膚結構·功能
  • 皮膚的疾病

第4章 主要皮膚疾病

  • 皮膚炎
  • 免疫疾病相關疾病
  • 免疫疾病性水泡性疾病
  • 扁平苔癬
  • 多形性紅斑
  • 乾癬
  • 治療
  • 乾癬治療的優點和風險
  • 乾癬開發平台
  • 乾癬市場
  • 皮膚感染疾病
  • 粉刺市場
  • 皮膚癌

第5章 皮膚科學產品:品牌別

第6章 現在·未來市場

  • 已發展的市場
  • 金磚四國市場

第7章 皮膚科學產業

  • 產業結構與趨勢
  • 企業簡介

第8章 附錄Ⅰ:用語

第9章 附錄Ⅱ:免疫疾病系

圖表清單

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHM127B

REPORT HIGHLIGHTS

The global market for skin disease treatment technologies reached $16.4 billion in 2014 and $17.1 billion in 2015. The market should reach $20.4 billion in 2020, demonstrating a compound annual growth rate (CAGR) of 3.6% from 2015 to 2020.

This report provides:

  • An overview of the global market for treatments of skin diseases, perhaps the most common of human afflications.
  • Analyses of global market trends, with data from 2014, 2015, and projections of compound annual growth rates (CAGRs) through 2020.
  • Focused coverage of four major categories of skin disease of exceptional medical and commercial significance: dermatitis (allergic and contact), cancers (including melanoma), immune disorders (including psoriasis), and infections (bacterial, fungal and viral).
  • Topics such as skin structure and function, diseases of the skin, current treatment options, and unmet clinical needs.
  • Discussion of the evolution of the market, including the rising prevalence of some skin diseases, and new diagnostic and treatment options.
  • Examination of the global market by product categories, such as anti-allergic products, antibacterials, antifungals, antivirals, immunotherapies, and anticancers.
  • Profiles of major players in the industry.

SCOPE OF REPORT

This report discusses the implications of the above-mentioned trends in the context of the current size and growth of the dermatology market, discussed both in global terms and in reference to the most important national markets. Long-standing and emerging companies are discussed, with profiles of their leadership and an update on M&A activity. Five-year global sales forecasts are provided for main drug categories, and breakdowns are provided for several national markets.

ANALYST'S CREDENTIALS

Paul Evers has been involved in analyzing pharmaceutical and medical markets for 20 years. He is the author of several previous BCC Research reports on diseases affecting different organ systems in addition to the skin.

Table of Contents

CHAPTER 1 - INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • SCOPE OF REPORT
  • MARKET ANALYSES AND FORECASTS
  • METHODOLOGY
  • INTENDED AUDIENCE
  • INFORMATION SOURCES
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 - SUMMARY

  • SKIN DISEASE AND ITS TREATMENT
    • DISEASES INCLUDED
    • TREATMENTS
  • ABOUT THE MARKET
    • LEADING COMPANIES
      • SUMMARY TABLE: GLOBAL MARKET FOR SKIN DISEASE TREATMENT TECHNOLOGIES BY REGION, THROUGH 2020 ($ MILLIONS)
      • SUMMARY FIGURE: GLOBAL MARKET FOR SKIN DISEASE TREATMENT TECHNOLOGIES BY REGION, 2013-2020 ($ MILLIONS)

CHAPTER 3 - OVERVIEW

  • SKIN STRUCTURE AND FUNCTIONS
    • STRUCTURE
      • Epidermis
      • Basement Membrane
      • Dermis
      • Hypodermis
    • FUNCTIONS
  • SKIN DISEASES

CHAPTER 4 - MAJOR SKIN DISEASES

  • DERMATITIS
    • SEBORRHEIC DERMATITIS
      • Available Treatments
    • ATOPIC DERMATITIS, ECZEMA
      • Available Treatments
    • CONTACT DERMATITIS
      • Irritant Contact Dermatitis
        • Available Treatments
      • Allergic Contact Dermatitis
        • Available Treatments
    • DERMATITIS PIPELINE
      • TABLE 1: PRODUCTS UNDERGOING RESEARCH AS POTENTIAL TREATMENTS FOR DERMATITIS
      • TABLE 2: GLOBAL MARKET FOR DERMATITIS BY TYPE, THROUGH 2020 ($ MILLIONS)
  • IMMUNE-RELATED CONDITIONS
    • LUPUS ERYTHEMATOSUS
      • Treatments Available
      • Pipeline
        • TABLE 3: COMPOUNDS UNDER DEVELOPMENT FOR CUTANEOUS LUPUS TREATMENT
    • IMMUNOBULLOUS DISEASES
      • Treatments Available
      • Market
        • TABLE 4: GLOBAL MARKET FOR IMMUNE-RELATED SKIN DISEASES BY TYPE, THROUGH 2020 ($ MILLIONS)
    • LICHEN PLANUS
      • Treatments Available
    • ERYTHEMA MULTIFORME
      • Treatments Available
  • PSORIASIS
    • SUBTYPES
      • Plaque Psoriasis
      • Guttate Psoriasis
      • Erythrodermic Psoriasis
      • Pustular Psoriasis
      • Psoriasis of the Nails
    • TREATMENTS AVAILABLE
      • Topical Therapies Available
        • Emollients
        • Keratolytics
        • Topical Corticosteroids
        • Vitamin D3 Products
        • Tazarotene
        • Tar Preparations
        • Anthralin
        • Topical Immunomodulators
        • Intralesional Therapy
        • Phototherapy with UVB
        • Photochemotherapy (PUVA)
      • Systemic Therapy
        • Methotrexate
        • Acitretin
        • Cyclosporine
        • Hydroxyurea
        • Cytokine Antagonists and Other Immunomodulators
    • PSORIASIS TREATMENT BENEFITS AND RISKS
    • MAJOR ENGINEERED PROTEIN TREATMENTS IN USE
      • Etanercept (Enbrel)
      • Adalimumab (Humira)
      • Infliximab (REMICADE)
      • Ustekinumab (STELARA)
      • Alefacept (Amevive)
      • Cost of Treatment
        • TABLE 5: COST OF PSORIASIS THERAPIES IN A TYPICAL WESTERN EUROPEAN COUNTRY ($)
    • PSORIASIS TREATMENT PIPELINE
    • PSORIASIS TREATMENT MARKET
      • TABLE 6: GLOBAL MARKET FOR PSORIASIS BY REGION, THROUGH 2020 ($ MILLIONS)
  • SKIN INFECTIONS
    • BACTERIAL INFECTIONS
      • Impetigo/Ecthyma
      • Cellulitis
        • Treatments Available
      • Necrotizing Subcutaneous Infection
        • Treatments Available
    • FUNGAL INFECTIONS
      • Candidiasis
        • Treatments Available
          • TABLE 7: ANTIFUNGALS FOR SUPERFICIAL FUNGAL INFECTIONS
      • Tinea Versicolor
        • Treatments Available
    • VIRAL INFECTIONS
      • Herpes Simplex
        • Treatments Available
      • Herpes Zoster
        • Treatments Available
      • Warts
        • Treatments Available
          • TABLE 8: ANTIVIRAL DRUGS AVAILABLE
    • SKIN INFECTION TREATMENT PIPELINE
      • TABLE 9: POTENTIAL DRUG CANDIDATES FOR SKIN INFECTION TREATMENTS
    • ANTI-INFECTIVE MARKET
      • TABLE 10: GLOBAL MARKET FOR SKIN INFECTIONS BY TYPE, THROUGH 2020 ($ MILLIONS)
    • ACNE
      • Comedonal
      • Papulopustular
      • Nodulocystic
      • Treatments Available
        • Retinoids
        • Antibiotics
        • Anti-inflammatory Drugs
        • Hormonal Therapy
      • Treatment Failure
    • ACNE TREATMENT PIPELINE
      • TABLE 11: POTENTIAL PRODUCTS FOR ACNE TREATMENT
    • ACNE TREATMENT MARKET
      • TABLE 12: GLOBAL MARKET FOR ACNE MEDICATIONS BY TYPE, THROUGH 2020 ($ MILLIONS)
  • SKIN CANCERS
    • MELANOMA
      • Treatments Available
    • NONMELANOMA SKIN CANCERS
      • Basal Cell Carcinoma
      • Squamous Cell Carcinoma
    • SKIN CANCER TREATMENT PIPELINE
      • TABLE 13: PRODUCTS IN PIPELINE FOR SKIN CANCER THERAPEUTICS
    • SKIN CANCER TREATMENT MARKET
      • TABLE 14: GLOBAL MARKET FOR SKIN CANCER THERAPEUTICS, THROUGH 2020 ($ MILLIONS)

CHAPTER 5 - DERMATOLOGY PRODUCTS

  • DESCRIPTIONS

CHAPTER 6 - CURRENT AND FORECAST MARKETS

  • DEVELOPED MARKETS
    • U.S.
      • TABLE 15: U.S. ANNUAL DIRECT COST OF PRESCRIPTION DRUGS, 2004 ($ MILLIONS)
      • TABLE 16: U.S. MARKET FOR PRESCRIPTION DERMATOLOGY DRUGS, THROUGH 2020 ($ MILLIONS/%)
    • JAPAN
      • TABLE 17: JAPANESE MARKET FOR PRESCRIPTION DERMATOLOGY DRUGS, THROUGH 2020 ($ MILLIONS/%)
    • GERMANY
      • TABLE 18: GERMAN MARKET FOR PRESCRIPTION DERMATOLOGY DRUGS, THROUGH 2020 ($ MILLIONS/%)
    • FRANCE
      • TABLE 19: FRENCH MARKET FOR PRESCRIPTION DERMATOLOGY DRUGS, THROUGH 2020 ($ MILLIONS/%)
    • ITALY
      • TABLE 20: ITALIAN MARKET FOR PRESCRIPTION DERMATOLOGY DRUGS, THROUGH 2020 ($ MILLIONS/%)
    • SPAIN
      • TABLE 21: SPAIN'S MARKET FOR PRESCRIPTION DERMATOLOGY DRUGS, THROUGH 2020 ($ MILLIONS/%)
    • UNITED KINGDOM
      • TABLE 22: U.K. MARKET FOR PRESCRIPTION DERMATOLOGY DRUGS, THROUGH 2020 ($ MILLIONS/%)
  • BRIC MARKETS
    • BRAZIL
      • TABLE 23: BRAZILIAN MARKET FOR PRESCRIPTION DERMATOLOGY DRUGS, THROUGH 2020 ($ MILLIONS/%)
    • RUSSIA
      • TABLE 24: RUSSIAN MARKET FOR PRESCRIPTION DERMATOLOGY DRUGS, THROUGH 2020 ($ MILLIONS/%)
    • INDIA
      • TABLE 25: INDIA'S MARKET FOR PRESCRIPTION DERMATOLOGY DRUGS, THROUGH 2020 ($ MILLIONS/%)
    • CHINA
      • TABLE 26: HEALTHCARE STATISTICS IN CHINA, 2006 VERSUS 2011 ($ BILLIONS/%)
      • TABLE 27: CHINESE MARKET FOR PRESCRIPTION DERMATOLOGY DRUGS, THROUGH 2020 ($ MILLIONS/%)

CHAPTER 7 - THE DERMATOLOGY INDUSTRY

  • INDUSTRY STRUCTURE AND TRENDS
  • COMPANY PROFILES
    • ABBVIE
    • AGENUS
    • AICURIS GMBH & CO. KG
    • ALLERGAN
    • ALMIRALL
    • AMGEN
    • ANACOR PHARMACEUTICALS INC.
    • ANGES MG
    • APEIRON BIOLOGICS AG
    • ASTELLAS PHARMA INC.
    • ASTION PHARMA A/S
    • ASTRAZENECA
    • BARRIER THERAPEUTICS
    • BASILEA PHARMACEUTICA LTD.
    • BRISTOL-MYERS SQUIBB
    • CELGENE
    • CIPHER PHARMACEUTICALS
    • DUSA PHARMACEUTICALS INC.
    • ELI LILLY
    • GALDERMA PHARMA SA/GALDERMA SA
    • GENENTECH
    • GLAXOSMITHKLINE
    • HANALL BIOPHARMA
    • IMMUNE TECHNOLOGIES & MEDICINE
    • INCYTE
    • JANSSEN BIOTECH
    • KAKEN PHARMACEUTICALS
    • LEO PHARMA A/S
    • MEDA AB
    • NANOBIO
    • NAVIDEA BIOPHARMACEUTICALS
    • NITRIC BIOTHERAPEUTICS
    • NOVARTIS INTERNATIONAL
    • PFIZER
    • PHOTOCURE
    • REGENERON PHARMACEUTICALS INC.
    • STIEFEL, A GSK COMPANY
    • SWITCH BIOTECH
    • VALEANT PHARMACEUTICALS INTERNATIONAL INC.

CHAPTER 8 - APPENDIX I: GLOSSARY

CHAPTER 9 - APPENDIX II: THE IMMUNE SYSTEM

  • TWO DEFENSE STRATEGIES
    • HUMORAL IMMUNITY
    • CELLULAR IMMUNITY
  • MARKERS OF SELF
  • HUMORAL IMMUNITY: B LYMPHOCYTES
  • CELLULAR IMMUNITY: T LYMPHOCYTES
    • REGULATORY T CELLS
    • CYTOTOXIC T CELLS
  • NATURAL IMMUNITY
    • TABLE 28: IMMUNOTHERAPEUTICS IN SKIN DISEASES

LIST OF TABLES

  • SUMMARY TABLE: GLOBAL MARKET FOR SKIN DISEASE TREATMENT TECHNOLOGIES BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 1: PRODUCTS UNDERGOING RESEARCH AS POTENTIAL TREATMENTS FOR DERMATITIS
    • TABLE 2: GLOBAL MARKET FOR DERMATITIS BY TYPE, THROUGH 2020 ($ MILLIONS)
    • TABLE 3: COMPOUNDS UNDER DEVELOPMENT FOR CUTANEOUS LUPUS TREATMENT
    • TABLE 4: GLOBAL MARKET FOR IMMUNE-RELATED SKIN DISEASES BY TYPE, THROUGH 2020 ($ MILLIONS)
    • TABLE 5: COST OF PSORIASIS THERAPIES IN A TYPICAL WESTERN EUROPEAN COUNTRY ($)
    • TABLE 6: GLOBAL MARKET FOR PSORIASIS BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 7: ANTIFUNGALS FOR SUPERFICIAL FUNGAL INFECTIONS
    • TABLE 8: ANTIVIRAL DRUGS AVAILABLE
    • TABLE 9: POTENTIAL DRUG CANDIDATES FOR SKIN INFECTION TREATMENTS
    • TABLE 10: GLOBAL MARKET FOR SKIN INFECTIONS BY TYPE, THROUGH 2020 ($ MILLIONS)
    • TABLE 11: POTENTIAL PRODUCTS FOR ACNE TREATMENT
    • TABLE 12: GLOBAL MARKET FOR ACNE MEDICATIONS BY TYPE, THROUGH 2020 ($ MILLIONS)
    • TABLE 13: PRODUCTS IN PIPELINE FOR SKIN CANCER THERAPEUTICS
    • TABLE 14: GLOBAL MARKET FOR SKIN CANCER THERAPEUTICS, THROUGH 2020 ($ MILLIONS)
    • TABLE 15: U.S. ANNUAL DIRECT COST OF PRESCRIPTION DRUGS, 2004 ($ MILLIONS)
    • TABLE 16: U.S. MARKET FOR PRESCRIPTION DERMATOLOGY DRUGS, THROUGH 2020 ($ MILLIONS/%)
    • TABLE 17: JAPANESE MARKET FOR PRESCRIPTION DERMATOLOGY DRUGS, THROUGH 2020 ($ MILLIONS/%)
    • TABLE 18: GERMAN MARKET FOR PRESCRIPTION DERMATOLOGY DRUGS, THROUGH 2020 ($ MILLIONS/%)
    • TABLE 19: FRENCH MARKET FOR PRESCRIPTION DERMATOLOGY DRUGS, THROUGH 2020 ($ MILLIONS/%)
    • TABLE 20: ITALIAN MARKET FOR PRESCRIPTION DERMATOLOGY DRUGS, THROUGH 2020 ($ MILLIONS/%)
    • TABLE 21: SPAIN'S MARKET FOR PRESCRIPTION DERMATOLOGY DRUGS, THROUGH 2020 ($ MILLIONS/%)
    • TABLE 22: U.K. MARKET FOR PRESCRIPTION DERMATOLOGY DRUGS, THROUGH 2020 ($ MILLIONS/%)
    • TABLE 23: BRAZILIAN MARKET FOR PRESCRIPTION DERMATOLOGY DRUGS, THROUGH 2020 ($ MILLIONS/%)
    • TABLE 24: RUSSIAN MARKET FOR PRESCRIPTION DERMATOLOGY DRUGS, THROUGH 2020 ($ MILLIONS/%)
    • TABLE 25: INDIA'S MARKET FOR PRESCRIPTION DERMATOLOGY DRUGS, THROUGH 2020 ($ MILLIONS/%)
    • TABLE 26: HEALTHCARE STATISTICS IN CHINA, 2006 VERSUS 2011 ($ BILLIONS/%)
    • TABLE 27: CHINESE MARKET FOR PRESCRIPTION DERMATOLOGY DRUGS, THROUGH 2020 ($ MILLIONS/%)
    • TABLE 28: IMMUNOTHERAPEUTICS IN SKIN DISEASES

LIST OF FIGURES

  • SUMMARY FIGURE: GLOBAL MARKET FOR SKIN DISEASE TREATMENT TECHNOLOGIES BY REGION, 2013-2020 ($ MILLIONS)
Back to Top